Literature DB >> 9368537

Clostridium difficile toxin A binding to human intestinal epithelial cells.

J A Smith1, D L Cooke, S Hyde, S P Borriello, R G Long.   

Abstract

Clostridium difficile radiolabelled toxin A ([3H]-toxin A) bound to human duodenal and colonic epithelial cells isolated from endoscopic biopsies. Binding was greater at 4 degrees C than 37 degrees C, consistent with the thermal binding characteristic of toxin A to a carbohydrate moiety. At 37 degrees C colonic cells bound significantly more [3H]-toxin A than duodenal cells. The amount of [3H]-toxin A binding varied considerably between individuals. [3H]-toxin A was displaced by unlabelled toxin A by 50% for duodenal cells and 70% for colonic cells with 94.3 nM unlabelled toxin A. Low non-displacable binding was observed in some samples at 4 degrees C and 37 degrees C, suggesting that these cells came from individuals incapable of specifically binding toxin. Pre-treating cells with alpha- or beta-galactosidases to cleave terminal alpha- and beta-galactose residues reduced [3H]-toxin A binding. There was also a reduction in [3H]-toxin A binding after heat treating cells, which is suggestive of protein binding. The reduction in binding varied between individuals. The reduction of [3H]-toxin A binding, after the removal of beta-linked galactose units, implicates these as components of the receptor and adds credence to the idea that the Lewis X, Y and I antigens may be involved in toxin A binding to human intestinal epithelial cells. However, because the Lewis antigens do not possess terminal alpha-galactose units, the reduction in binding after alpha-galactosidase treatment suggests that other receptors may be involved in toxin A binding to some human intestinal cells. These data are the first demonstration of direct toxin A binding to human intestinal epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9368537     DOI: 10.1099/00222615-46-11-953

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  6 in total

Review 1.  Clostridium difficile toxins: mechanism of action and role in disease.

Authors:  Daniel E Voth; Jimmy D Ballard
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

Review 2.  Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.

Authors:  Lauren E Hudson; Sarah E Anderson; Anita H Corbett; Tracey J Lamb
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

3.  Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile.

Authors:  Melinda A Engevik; Kristen A Engevik; Mary Beth Yacyshyn; Jiang Wang; Daniel J Hassett; Benjamin Darien; Bruce R Yacyshyn; Roger T Worrell
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-12-31       Impact factor: 4.052

4.  Human Clostridium difficile infection: altered mucus production and composition.

Authors:  Melinda A Engevik; Mary Beth Yacyshyn; Kristen A Engevik; Jiang Wang; Benjamin Darien; Daniel J Hassett; Bruce R Yacyshyn; Roger T Worrell
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-12-31       Impact factor: 4.052

5.  Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.

Authors:  S J Ward; G Douce; D Figueiredo; G Dougan; B W Wren
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

6.  Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile.

Authors:  S J Ward; G Douce; G Dougan; B W Wren
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.